Halle, Germany facility demonstrates operational excellence principles and innovative manufacturing concepts with state-of-the-art isolator tecnology
Halle/Westfalen, Germany, February 22, 2016 – Baxter’s BioPharma Solutions business, a premier contract manufacturing organization (CMO) that specializes in parenteral pharmaceuticals, is pleased to announce that the company’s oncology manufacturing facility expansion in Halle, Germany is a winner of the 2016 Facility of the Year Award (FOYA) in the category of Operational Excellence.
The International Society for Pharmaceutical Engineering (ISPE) Facility of the Year Awards (FOYA) is a premier global awards program recognizing innovation and creativity in manufacturing facilities that serve the regulated healthcare industry.
Baxter’s Halle facility team was recognized for undertaking a challenging project to add additional capacity to service the CMO market of parenteral oncology products, while avoiding impact on current operations and customers.
“We are honored to be recognized with this prestigious award. Cancer incidence continues to rise, and this completed expansion offers not only capacity but innovative processes and technologies that will allow Baxter to stay at the forefront of parenteral manufacturing for oncology therapies,” said Dr. Burkhard Wichert, Vice President of Manufacturing for Baxter’s BioPharma Solutions business. “We take our commitment to world-class contract manufacturing of oncology products seriously, and understand that the better we can serve our customers, the better they can serve patients around the world.”
Baxter applied operational excellence principals to innovative manufacturing concepts with state-of-the-art technology, combined with high flexibility for rapid changeover and broad flexibility to manufacture a wide variety of liquid formulations (including organic solvents, biologics, suspensions) in a combination that helps assure product quality and economical manufacturing.
The expanded facility in Halle was designed by Baxter in-house engineers with extensive experience in sterile manufacturing as an evolution of the reliable processes and equipment on-site. This includes new equipment combined with innovative disinfection systems and an optimized layout to improve efficiency, prevent contamination and keep potential losses on the filling line to a minimum. Extensive use of glass throughout the expansion area significantly improves visibility for workers and visitors to strengthen the applied LEAN philosphy. The result was to provide full services “under one roof” that facilitate short startup time and minimize transfer costs. The additional capacity reinforces BioPharma Solutions‘ leadership position as one of the largest capacity CMOs for lyophilized cytotoxic parenterals.
About Baxter’s BioPharma Solutions Business
Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise, sterile manufacturing solutions, parenteral delivery systems and customized support services needed to meet the unique challenges that parenteral products face.
For more information, please visit
www.baxterbiopharmasolutions.com.
Media Contact:
Eric Tatro
1-224-948-3007
About the Facility of the Year Awards
The Facility of the Year Awards recognize state-of-theart
projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and maufacturing industry to showcase its accomplishments in facility design, construction, and operation, while sharing the development of new applications of technology and cutting-edge approaches. For more information contact:
Maria Robertson
Senior Director, Marketing Communicatio
